Announcement on the Holding Subsidiary's Obtaining of the "Drug GMP Certificate"
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: Pro 2019-034
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement
for the authenticity, accuracy and completeness of its contents.
Recently, Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the company") holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical")
received the "Drug GMP Certificate" issued by Zhejiang Food and Drug Administration. The relevant information is hereby announced as follows:
1. GMPCertification Related Information
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.Address: No. 58
Certificate No.: ZJ20190116
Certification Scope: powder injection (including cephalosporins) and freeze-dried powder injection
certification date: 2019
10 31
valid: 202410 30
2. GMPCertificate Involving Production Line
| Production Line Name |
Design Annual Capacity |
Main Variety |
| Powder Injection Production Line |
about 2000 |
cefmenoxime hydrochloride for injection, cefoxitin sodium for injection |
| freeze-dried powder injection production line |
about 1000 |
penciclovir for injection, for injection ribavirin |
| Drug Name |
Dosage Form |
Therapeutic Field |
Manufacturer |
| Injection Cefmenoxime Hydrochloride |
Powder Injection (Including Cephalosporins) |
Anti-infection |
Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., Liaoning Haisco Pharmaceutical Co., Ltd., Hainan Tianhuang Pharmaceutical Co., Ltd., Hainan Lingkang Pharmaceutical Co., Ltd. and Jianfeng Pharmaceutical Co., Ltd. and other 10 . |
| Injection Cefoxitin Sodium |
Powder Injection (Including Cephalosporins) |
Anti-infection |
Harbin Pharmaceutical Group Pharmaceutical General Factory, Guangdong Bozhou Pharmaceutical Co., Ltd., Sichuan Pharmaceutical Preparation Co., Ltd., Shandong Luoxin Pharmaceutical Group Co., Ltd. and Jianfeng Pharmaceutical Co., etc. 49 home. |
| Penciclovir for Injection |
Freeze-dried Powder Injection |
Antivirus |
Ruiyang Pharmaceutical Co., Ltd. and Jianfeng Pharmaceutical . |
Ribavirin for Injection |
Freeze-dried Powder Injection |
Antivirus |
Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., Zhejiang Asia Pacific Pharmaceutical Co., Ltd., Haikou Qili Pharmaceutical Co., Ltd., Hainan General Kangli Pharmaceutical Co., Ltd. and Jianfeng Pharmaceutical Co., Ltd. 209 7 . |
, "Major Manufacturers " information in the above table mainly comes from the website of china food and drug administration;
4. Impact on Listed Companies and Risk TipsThe "GMP
Certificate" obtained by Jianfeng Pharmaceutical Co., Ltd. this time is that its original GMP certificate for powder injection and freeze-dried powder injection production line expires and obtains the certificate after re-certification. Re-obtaining the GMP certificate will help ensure the production capacity of the above-mentioned products and ensure the continuity of market supply. It will not have a significant impact on the Company's current operations. The future sales of various drugs of
Company may be affected by the market environment, industry policies, supply and demand and other factors, with certain uncertainties. Please the majority of investors cautious decision-making, pay attention to prevent investment risk.hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
November 6
, 2019
More information
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-22
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-30
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
Chairman Jiang Xiaomeng Directs Work in Yunnan Peak
On December 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, went to Yunnan Jianfeng cement company to investigate and guide the work. On the morning of the same day, accompanied by the Yunnan peak management team, Jiang Xiaomeng went deep into the front line and successively went to the central control room of the production and manufacturing department, the raw material clay yard, the lignite yard and other areas for field investigation and investigation to understand the problems existing in the production and operation process. Subsequently, a business analysis meeting was held to make a comparative analysis of the various business indicators of Yunnan Jianfeng from January to November this year, and put forward two requirements to the management team: further strengthen internal management and improve execution; strengthen the coordination of external relations, and improve The ability and level of enterprise resource acquisition. At the Yunnan Jianfeng middle-level cadre meeting held on the afternoon of the 16th, Jiang Xiaomeng first fully affirmed Yunnan Jianfeng's highest output and best benefits since it was put into production in 2018, and expressed his gratitude to all cadres and employees of Yunnan Jianfeng for their hard work. After that, Jiang Xiaomeng made a detailed analysis of the cement industry and the regional market environment in Yunnan, and combined with the current production and operation situation of Yunnan Jianfeng, put forward the focus of the next step: 1. should fully attach importance to and mobilize the initiative and responsibility of employees at all levels to improve the overall execution of the team; 2. raw material mines are an important factor restricting the future development of cement enterprises, which should be paid full attention to and formulate clear strategies and methods, set out a timetable to obtain future production resources as much as possible; 3. continuously advocate and promote technological innovation, keep pace with the times, continuously improve production management, equipment management, production technology level, and maintain the competitive advantage of the industry; 4. further strengthen production
2020
07-31